World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain
LONDON, March 27, 2024 /PRNewswire/ -- Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI®, Telix's miniature robotic-assisted gamma pro...
QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy
MELBOURNE, Australia and DRESDEN, Germany, March 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement to commercially partner the QDOSE® dosimetry software platform with ABX-CRO Advanced Pharmaceutical Services...
Appointment of Dr Darren Patti to Group Chief Operating Officer
MELBOURNE, Australia, March 12, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr.Darren Patti as Group Chief Operating Officer (COO), effective 11 March 2024. Dr. Patti joined Telix in March 2021 to lead the Company'...
Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform
MELBOURNE, Australia, March 5, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manuf...
Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics
MELBOURNE, Australia, Feb. 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based inA...
Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline
MELBOURNE, Australia, Feb. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its results for the financial year ended31 December 2023. All figures are in AUD$ unless otherwise stated.[1] 2023 highlights * Total Group revenue of $502.5M, an...
Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform
MELBOURNE, Australia , Feb. 8, 2024 /PRNewswire/ --.Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United...
Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)
MELBOURNE, Australia, Jan. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company's theranostic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024) to be he...
Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference
MELBOURNE, Australia, Jan. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that DrChristian Behrenbruch, Managing Director and Group CEO, will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference inSan Francisco, CA (US). The pre...
Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer
MELBOURNE, Australia and INDIANAPOLIS, Dec. 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) tothe United States (U.S.) Food and Drug Administration (FDA) for its investigational pos...
First Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix's Breakthrough Kidney Cancer Imaging Agent
MELBOURNE, Australia and INDIANAPOLIS, Dec. 11, 2023 /PRNewswire/ -- Telix
Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the
first patient has been dosed in aUnited States (U.S.) expanded access program
(EAP, ClinicalTrials.gov ID:NCT06090331
Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS
MELBOURNE, Australia, Dec. 7, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces positive topline results from the Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imag...
First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent
MELBOURNE, Australia and LIÉGE, Belgium, Dec. 4, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a named patient (early access) program inthe Netherlands for its investigational positron emission tomography...
Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS
MELBOURNE, Australia, Nov. 30, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candid...
Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®
MELBOURNE, Australia, Nov. 14, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed a conditional Term Sheet to acquire QSAM Biosciences, Inc. (QSAM) and its lead asset, CycloSam® (Samarium-153-DOTMP). QSAM is a United States (U.S.) based...
Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery
MELBOURNE, Australia and PARIS, Nov. 13, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) andParis-based Mauna Kea Technologies (Euronext Growth: ALMKT,Mauna Kea), today announce an expansion of the IRiS (Imaging and Robotics in Surgery) Alliance[1] through a stra...
First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591
MELBOURNE, Australia, Nov. 13, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company's Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen (PSMA) targeting radio...
Telix to Present at Jefferies London Healthcare Conference 2023
MELBOURNE, Australia, Nov. 9, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that DrChristian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies London Healthcare Conference 2023. The presentation will take place o...
Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region
MELBOURNE, Australia, Nov. 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed an exclusive agreement withDenmark-based WIIK Pharma ApS (Wiik Pharma) for the distribution of Telix's investigational prostate cancer imaging agent, Illuc...
ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability
* The study has achieved its primary objectives, confirming the safety and tolerability profile of TLX591 administered in two doses, two weeks apart in combination with standard of care (SoC) * Preliminary activity demonstrates meaningful PSA[1] reduction; monitoring of patients is ongoing, i...
